Targeting the androgen receptor in breast cancer (Q38349376)

2 September 2017

1 reference

title

Targeting the androgen receptor in breast cancer (English)

1 reference

2 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Keeming Chia

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Elgene Lim

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Megan O'Brien

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

1 February 2015

1 reference

2 September 2017

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Targeting androgen receptor in estrogen receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

ARN-509: a novel antiandrogen for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Evolution of androgen receptor targeted therapy for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor expression and breast cancer survival in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Increased STAT1 signaling in endocrine-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Identification of molecular apocrine breast tumours by microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Amplitude modulation of androgen signaling by c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0427-8

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

21 January 2018

1 reference

12 December 2020

Species-specific pharmacology of antiestrogens: role of metabolism

1 reference

12 December 2020

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

1 reference

12 December 2020

Therapeutic activity of testoterone in metastatic breast cancer

1 reference

12 December 2020

TESTOSTERONE PROPIONATE THERAPY IN BREAST CANCER

1 reference

12 December 2020

Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

1 reference

12 December 2020

Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients

1 reference

12 December 2020

Calusterone (7beta,17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer

1 reference

12 December 2020

Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7

1 reference

12 December 2020

10.1007/S11912-014-0427-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

1020515902

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25665553%20AND%20SRC:MED&resulttype=core&format=json